By Doug Macron

Santaris Pharma last month said that it has advanced two hypercholesterolemia drug-development programs further within its preclinical pipeline, with one poised to enter human testing next year.

And while the locked nucleic acid technology upon which the drugs are based is novel, the targets are currently being pursued by at least three major RNAi and antisense firms, which could set the stage for a showdown between the three therapeutic modalities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.